Ranbaxy drugs in US to be phased out

Sun Pharmaceutical plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories products in the US after completing a $3.2-billion takeover of its loss-making rival, sources with direct knowledge of the matter said. Ranbaxy drugs sold in the US will be gradually rebranded as Sun treatments as part of a strategy to turn around the company. The brand is likely to continue to be present in other markets, the sources said.